A Proof-of-Concept Study for Ilorasertib (ABT-348) Activity in Patients With CDKN2A-Deficient Advanced Solid Cancers: a Phase II Basket Trial

Trial Profile

A Proof-of-Concept Study for Ilorasertib (ABT-348) Activity in Patients With CDKN2A-Deficient Advanced Solid Cancers: a Phase II Basket Trial

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Aug 2016

At a glance

  • Drugs Ilorasertib (Primary)
  • Indications Solid tumours
  • Focus Proof of concept; Therapeutic Use
  • Acronyms Basket
  • Most Recent Events

    • 22 Aug 2016 Status changed from not yet recruiting to recruiting.
    • 05 Aug 2016 Planned primary completion date changed from 1 Oct 2022 to 1 Aug 2022.
    • 05 Aug 2016 Planned initiation date changed from 1 Oct 2016 to 1 Aug 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top